Trial Profile
Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Oct 2016 Results of pooled analysis of three phase III trials (JMDB, PARAMOUNT and JMII; n=1064) were presented at the 41st European Society for Medical Oncology Congress
- 06 Aug 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.